Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
64.03
+8.01 (+14.30%)
Streaming Delayed Price
Updated: 11:28 AM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
4 Analysts Have This to Say About Travere Therapeutics
↗
December 05, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
↗
December 05, 2022
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
↗
December 05, 2022
Via
Benzinga
Recap: Travere Therapeutics Q3 Earnings
↗
October 27, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA
↗
October 14, 2022
Via
Benzinga
Expert Ratings for Travere Therapeutics
↗
October 14, 2022
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
November 22, 2022
During Tuesday's trading, 160 companies set new 52-week lows.
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 15, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease
↗
October 14, 2022
Via
Benzinga
Travere Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Earnings Perspective: Return On Capital Employed
↗
November 03, 2022
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter.
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
↗
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Return On Capital Employed Overview
↗
August 15, 2022
Via
Benzinga
Recap: Travere Therapeutics Q2 Earnings
↗
August 04, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For October 27, 2022
↗
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 26, 2022
Data support the Company’s lead investigational product candidate sparsentan
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Earnings Outlook For Travere Therapeutics
↗
October 26, 2022
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 20, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 13, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
121 Stocks That Hit Their 52-Week Low
↗
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
↗
October 05, 2022
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.
Via
InvestorPlace
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
↗
August 22, 2022
Via
Benzinga
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
↗
August 22, 2022
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
↗
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication
↗
August 04, 2022
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 03, 2022
Gainers
Via
Benzinga
4 Analysts Have This to Say About Travere Therapeutics
↗
July 26, 2022
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
